@article{ab929cb3e1fb448ba1c61cfb59456dd7,
title = "Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement",
abstract = "Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.",
keywords = "Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Arthritis, Rheumatoid, Consensus, Humans, Interleukin-6, Spondylitis, Ankylosing, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Arthritis, Rheumatoid, Consensus, Humans, Interleukin-6, Spondylitis, Ankylosing",
author = "Gianfranco Ferraccioli and Schoels, {Monika M.} and {Van Der Heijde}, D{\'e}sir{\'e}e and Breedveld, {Ferdinand C.} and Burmester, {Gerd R.} and Maxime Dougados and Paul Emery and Cem Gabay and Allan Gibofsky and Gomez-Reino, {Juan Jesus} and Graeme Jones and Kvien, {Tore K.} and Murikama, {Miho M.} and Norihiro Nishimoto and Smolen, {Josef S.}",
year = "2013",
doi = "10.1136/annrheumdis-2012-202470",
language = "English",
volume = "72",
pages = "583--589",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "London: BMJ Publishing.",
}